https://www.selleckchem.com/pr....oducts/nmda-n-methyl
Platinum-based chemotherapy was the predominant first-line therapy, with programmed cell death-1/programmed cell death-ligand-1 inhibitors as subsequent lines of therapy. The NF1 mutation only group had numerically the shortest median rwPFS (82 days) than other mutation groups. Median OS for the NF1 mutation group in first, second, and third lines of therapy was 321, 498, and 210 days, respectively. NF1 mutations confer distinct clinical characteristics in patients with mNSCLC. These patients may have different tra
Gefällt mir
Kommentar
Teilen
